Shiqiang Qu

No ORCID on file · 3 papers in corpus · active 2014-2022

Study types

  • article 3
article 2022
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study
·doi:10.1002/hon.3026

Ruxolitinib is a safe and effective therapy of myeloproliferative neoplasm-associated (MPN) myelofibrosis. However, often there are dose reductions and/or therapy interruptions because of therapy-related adverse events (AEs), especially ane…

article 2018
Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response
·doi:10.1038/s41408-017-0029-4

Abstract Low-dose thalidomide and prednisone alone or combined are effective therapies in some persons with primary myelofibrosis (PMF) and anemia with or with RBC transfusion dependence. Danazol is also effective in some persons with PMF a…

article 2014
[Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
·doi:10.3760/cma.j.issn.0253-2727.2014.08.006

OBJECTIVE: To observe the clinical effects of low-dose thalidomide (THAL) and prednisone (PRED) with or without danazol (DANA) in patients with primary myelofibrosis (PMF) associated anemia. METHODS: A cohort of 58 PMF patients with anemia …